AG-490 (Tyrphostin B42)

Name: AG-490 (Tyrphostin B42)
Brand: Selleck Chemicals
SKU: S1143
Rating: 5 (99 reviews)

For research use only.

Catalog No.S1143 Synonyms: Zinc02557947

99 publications

AG-490 (Tyrphostin B42) Chemical Structure

CAS No. 133550-30-8

AG-490 (Tyrphostin B42, Zinc02557947) is an inhibitor of EGFR with IC50 of 0.1 μM in cell-free assays, 135-fold more selective for EGFR versus ErbB2, also inhibits JAK2 with no activity to Lck, Lyn, Btk, Syk and Src.

Selleck's AG-490 (Tyrphostin B42) has been cited by 99 publications

Oncol Rep, 2021, 10.3892/or.2021.7926

PubMed: 33432366 ( click the link to review the publication )

Acta Neuropathol, 2020, 10.1007/s00401-020-02226-7

PubMed: 33009951 ( click the link to review the publication )

Aging (Albany NY), 2020, 12(18):18084-18098

PubMed: 32957082 ( click the link to review the publication )

Carcinogenesis, 2020, 41(7):993-1004

PubMed: 31740922 ( click the link to review the publication )

Oncogenesis, 2020, 10;9(2):15

PubMed: 32041943 ( click the link to review the publication )

Front Pharmacol, 2020, 26;11:273

PubMed: 32273843 ( click the link to review the publication )

J Neurodev Disord, 2020, 12(1):29

PubMed: 33172406 ( click the link to review the publication )

Food Funct, 2020, 11(5):3941-3951

PubMed: 32338270 ( click the link to review the publication )

BMC Cancer, 2020, 20(1):632

PubMed: 32641093 ( click the link to review the publication )

Mol Cells, 2020, 43(8):749-762

PubMed: 32868491 ( click the link to review the publication )

Exp Biol Med (Maywood), 2020, 245(7):654-666

PubMed: 32075431 ( click the link to review the publication )

J Appl Toxicol, 2020, 24

PubMed: 32212198 ( click the link to review the publication )

Connect Tissue Res, 2020, 5;1-16

PubMed: 32370570 ( click the link to review the publication )

J Interferon Cytokine Res, 2020, 40(2):116-124

PubMed: 31834821 ( click the link to review the publication )

Int J Med Sci, 2020, 17(18):3174-3189

PubMed: 33173437 ( click the link to review the publication )

Pharmazie, 2020, 75(6):255-260

PubMed: 32539921 ( click the link to review the publication )

Arch Biochem Biophys, 2020, 685:108330

PubMed: 32156533 ( click the link to review the publication )

Cell Prolif, 2020, 53(8):e12856

PubMed: 32648622 ( click the link to review the publication )

Mol Med Rep, 2020, 21(1):89-96

PubMed: 31746349 ( click the link to review the publication )

Virus Res, 2020, 281:197907

PubMed: 32113834 ( click the link to review the publication )

J Cancer, 2020, 11(16):4771-4782

PubMed: 32626524 ( click the link to review the publication )

Biochem Biophys Res Commun, 2020, 521(2):360-367

PubMed: 31668806 ( click the link to review the publication )

Oxid Med Cell Longev, 2020, 2020:9187406

PubMed: 32832009 ( click the link to review the publication )

J Surg Res, 2020, 248:98-108

PubMed: 31877436 ( click the link to review the publication )
Biochem Biophys Res Commun, 2020, 524(4):963-969

PubMed: 32059851 ( click the link to review the publication )

Anim Biotechnol, 2020, 1-13

PubMed: 32657254 ( click the link to review the publication )

Cancers (Basel), 2019, 11(12)E1939

PubMed: 31817171 ( click the link to review the publication )

Cancer Discov, 2019, 9(6):756-777

PubMed: 30862724 ( click the link to review the publication )

Aging (Albany NY), 2019, 11(17):6674-6690

PubMed: 31481647 ( click the link to review the publication )

J Cell Physiol, 2019, 234(9):15395-15406

PubMed: 30710340 ( click the link to review the publication )

J Cell Physiol, 2019, 234(11):21182-21192

PubMed: 31032948 ( click the link to review the publication )

Int J Biol Sci, 2019, 15(9):1882-1891

PubMed: 31523190 ( click the link to review the publication )

Cancer Cell Int, 2019, 19:57

PubMed: 30918473 ( click the link to review the publication )

Front Pharmacol, 2019, 10:620

PubMed: 31231218 ( click the link to review the publication )

Toxicol Appl Pharmacol, 2019, 362:59-66

PubMed: 30352208 ( click the link to review the publication )

Eur J Pharmacol, 2019, 854:289-297

PubMed: 31004602 ( click the link to review the publication )

Onco Targets Ther, 2019, 12:9069-9076

PubMed: 31802914 ( click the link to review the publication )

Oral Dis, 2019, 25(7):1769-1779

PubMed: 31365165 ( click the link to review the publication )

Can Respir J, 2019, 2019:2697376

PubMed: 31379980 ( click the link to review the publication )

Clin Cancer Res, 2018, 24(10):2417-2429

PubMed: 29463558 ( click the link to review the publication )

J Cell Physiol, 2018, 234(1):454-463

PubMed: 29932210 ( click the link to review the publication )

Mol Carcinog, 2018, 57(3):429-439

PubMed: 29215754 ( click the link to review the publication )

Biomed Pharmacother, 2018, 101:107-114

PubMed: 29477470 ( click the link to review the publication )

Int J Oncol, 2018, 52(5):1515-1527

PubMed: 29512698 ( click the link to review the publication )

Toxicology, 2018, 408:62-69

PubMed: 29981841 ( click the link to review the publication )

Am J Transl Res, 2018, 10(2):465-473

PubMed: 29511440 ( click the link to review the publication )

Eur J Pharmacol, 2018, 833:221-229

PubMed: 29890157 ( click the link to review the publication )

Oncol Rep, 2018, 39(4):1892-1900

PubMed: 29393444 ( click the link to review the publication )
Biomed Res Int, 2018, 2018:2548378

PubMed: 30363706 ( click the link to review the publication )

Neurosci Lett, 2018, 662:219-226

PubMed: 29061394 ( click the link to review the publication )

Oncol Lett, 2018, 16(2):2517-2524

PubMed: 30013646 ( click the link to review the publication )

Int Urol Nephrol, 2018, 50(8):1535-1544

PubMed: 29508174 ( click the link to review the publication )

Antioxid Redox Signal, 2017, 27(5):251-268

PubMed: 27923278 ( click the link to review the publication )

Cardiovasc Res, 2017, 113(3):310-320

PubMed: 28158495 ( click the link to review the publication )

Cell Physiol Biochem, 2017, 44(1):293-302

PubMed: 29132131 ( click the link to review the publication )

Int J Mol Sci, 2017, 18(12)

PubMed: 29206176 ( click the link to review the publication )

Am J Transl Res, 2017, 9(10):4617-4626

PubMed: 29118922 ( click the link to review the publication )

Brain Res, 2017, 15;1657:202-207

PubMed: 27998796 ( click the link to review the publication )

Drug Des Devel Ther, 2017, 11:2787-2799

PubMed: 29033541 ( click the link to review the publication )

Biosci Rep, 2017, 37(6)BSR20171038

PubMed: 29074558 ( click the link to review the publication )

PLoS One, 2017, 12(1):e0169665

PubMed: 28068414 ( click the link to review the publication )

Onco Targets Ther, 2017, 10:5329-5336

PubMed: 29184419 ( click the link to review the publication )

Cell Biol Int, 2017, 41(6):659-668

PubMed: 28378938 ( click the link to review the publication )

Evid Based Complement Alternat Med, 2017, 2017:2942830

PubMed: 28630633 ( click the link to review the publication )

Oncotarget, 2017, 8(57):96993-97008

PubMed: 29228588 ( click the link to review the publication )

Oncotarget, 2017, 8(57):96958-96969

PubMed: 29228585 ( click the link to review the publication )

Oncotarget, 2017, 8(39):64853-64866

PubMed: 29029396 ( click the link to review the publication )

Oncotarget, 2017, 8(28):45848-45861

PubMed: 28507278 ( click the link to review the publication )

Oncogene, 2016,

PubMed: 26804171 ( click the link to review the publication )

PLoS Pathog, 2016, 12(4):e1005605

PubMed: 27128969 ( click the link to review the publication )

Stem Cells Transl Med, 2016, 5(7):960-9

PubMed: 27130223 ( click the link to review the publication )

Clin Exp Immunol, 2016, 184(2):147-58

PubMed: 26646950 ( click the link to review the publication )
Cellular Signalling, 2016, 19;28(6):652-662

PubMed: 27006333 ( click the link to review the publication )

Inflamm Res, 2016, 65(3):193-202

PubMed: 26621504 ( click the link to review the publication )

Int J Mol Med, 2016, 38(4):1125-34

PubMed: 27599586 ( click the link to review the publication )

J Bone Miner Metab, 2016, [Epub ahead of print]

PubMed: 27628046 ( click the link to review the publication )

Scand J Immunol, 2016,

PubMed: 26482544 ( click the link to review the publication )

Mol Med Rep, 2016, 13(4):3684-90

PubMed: 26936086 ( click the link to review the publication )

Oncotarget, 2016, 7(27):41445-41459

PubMed: 27213590 ( click the link to review the publication )

J Am Soc Nephrol, 2016, 27(10):3105-3116

PubMed: 27694161 ( click the link to review the publication )

Cancer Lett, 2015, 359(2):335-43

PubMed: 25641338 ( click the link to review the publication )

Carcinogenesis, 2015, 36(1):142-50

PubMed: 25411359 ( click the link to review the publication )

Carcinogenesis, 2015, 36(1):142-50

PubMed: ( click the link to review the publication )

Neoplasia, 2015, 17(8):625-33

PubMed: 26408255 ( click the link to review the publication )

Eur Neuropsychopharmacol, 2015, 25(8):1287-99

PubMed: 25979764 ( click the link to review the publication )

Eur Neuropsychopharm, 2015, 10.1016/j.euroneuro.2015.04.020

PubMed: ( click the link to review the publication )

Int J Neuropsychopharmacol, 2015, 19(2)

PubMed: 26438799 ( click the link to review the publication )

Oncol Rep, 2015, 34(4):1875-82

PubMed: 26238612 ( click the link to review the publication )

J Geriatr Cardiol, 2015, 12(6):591-9

PubMed: 26788034 ( click the link to review the publication )

Mol Cancer, 2014, 13:176

PubMed: 25047660 ( click the link to review the publication )

Carcinogenesis, 2014, 35(4):795-806

PubMed: 24265293 ( click the link to review the publication )

Mol Cell Biol, 2014, 34(24):4368-78

PubMed: 25312644 ( click the link to review the publication )

Am J Physiol Cell Physiol, 2014, 307(7):C597-605

PubMed: 24944200 ( click the link to review the publication )

Oncotarget, 2014, 5(16):7051-64

PubMed: 25216522 ( click the link to review the publication )

Clin Cancer Res, 2013, 19(17):4697-705

PubMed: 23857601 ( click the link to review the publication )

Cancer Lett, 2013, 341(2):224-30

PubMed: 23941832 ( click the link to review the publication )
Biochem Biophys Res Commun, 2013, 429(3-4):156-62

PubMed: 23142594 ( click the link to review the publication )

Biochem Biophys Res Commun, 2013, 435(4):533-9

PubMed: 23665018 ( click the link to review the publication )

Prostate, 2012, 73(3):267-77

PubMed: 22821817 ( click the link to review the publication )

Purity & Quality Control

Choose Selective EGFR Inhibitors

Biological Activity

Description

Targets

JAK2 (V617F) ^[8] ()	EGFR ^[1] (Cell-free assay)
	0.1 μM

In vitro

AG-490 inhibits HER-2 driven cell proliferation with IC50 of 3.5 μM. ^[1] Corresponding to the specific dose-dependent inhibition of constitutively activated JAK2 in pre-B acute leukemia (ALL) cells, AG-490 (5 μM) almost completely blocks the growth of all ALL cells by inducing programmed cell death, with no deleterious effect on normal hematopoiesis. AG-490 does not inhibit the activities of Lck, Lyn, Btk, Syk, and Src. ^[2] AG-490 (60-100 μM) blocks the constitutive activation of Stat3sm, and inhibits spontaneous as well as interleukin 2-induced growth of mycosis fungoides (MF) tumor cells with IC50 values of 75 μM and 20 μM, respectively. ^[3] AG-490 potently inhibits IL-2-mediated human T cell growth with an IC50 of 25 μM by blocking the activities of JAK3 and STAT5a/b. ^[4] Although AG-490 alone has no effect on proliferation of FDrv210H cells at a concentration of 5 μM, AG-490 can synergize with STI571 to enhance its inhibitory effect on p210^bcr-abl driven proliferation. ^[5] AG-490 significantly inhibits the constitutive activation of Stat3 in MOPC, MPC11, and S194 cells, leading to dramatic dose-dependent apoptosis. ^[6] AG-490 (100 μM) inhibits Akt phosphorylation, inhibits the activation of nuclear factor-κB, and causes the activation of GSK-3β, leading to the reduction of c-Myc. AG-490 (50 μM) can induce apoptosis of imatinib-resistant BaF3 cells expressing T315I and E255K mutants of Bcr-Abl. ^[7] AG-490 at 30 μM inhibits not only Epo-induced phosphorylation of wild-type JAK2 but also constitutive phosphorylation of the JAK2 V617F mutant. AG-490 also potently inhibits cytokine-independent cell growth induced by the JAK2 V617F mutant in BaF3 cells. ^[8]

Cell Data

Cell Lines	Assay Type	Concentration	Incubation Time	Formulation	Activity Description	PMID
BC3	MVHGeY5kfGmxbjDBd5NigQ>?	MYexNFDjiIoEtV2=	NFvJOpczPCCq		NHPvSnpu\WSrYYTld{BRTUxiY3XscEBieG:ydH;zbZM>	NF3jR\|EzPjF6NEm5PS=>
BCBL1	MlrISpVv[3Srb36gRZN{[Xl?	M3HHblExOOLCidM1US=>	NXjZeXI6OjRiaB?=		NYP5WJpSdWWmaXH0[ZMhWEWOIHPlcIwh[XCxcITvd4l{	MkXUNlYyQDR7OUm=
BC3	MUXGeY5kfGmxbjDBd5NigQ>?	NGP1WIMyODEkgJpCuW0>	NX34bFZxOjRiaB?=		MknmcYVlcWG2ZYOg[IUueGixc4Doc5J6dGG2aX;uJI9nKFOWQWSzJINwenKnbHH0[YQhf2m2aDDIV3A4OCCjbnSgTHNHOSC{ZXT1Z5Rqd25?	NHfHW2MzPjF6NEm5PS=>
BCBL1	M{TG[WZ2dmO2aX;uJGF{e2G7	M3WzV\|ExOOLCidM1US=>	Mly5NlQhcA>?		NEGzdJNu\WSrYYTld{Bl\S2yaH;zdIhwenmuYYTpc44hd2ZiU2TBWFMh[2:{cnXsZZRm\CC5aYToJGhUWDdyIHHu[EBJW0Z{IILl[JVkfGmxbh?=	NWXoOmp5OjZzOES5PVk>
BC3	MVPGeY5kfGmxbjDBd5NigQ>?	Mn7SNVAx6oDLwsXN	NX\MWZE4OjRiaB?=		MWLpcoR2[2W\|IHGgZ49ueGyndHWgZZV1d3CqYXfpZ{BndHW6wrC=	MoDTNlYyQDR7OUm=
BCBL1	M1nsXmZ2dmO2aX;uJGF{e2G7	MoLLNVAx6oDLwsXN	NI[4d\|IzPCCq		NFzIfVRqdmS3Y3XzJIEh[2:vcHzleIUh[XW2b4DoZYdq[yCobIX4xsA>	NGPGVnczPjF6NEm5PS=>
SK-MEL-28	Mm\CSpVv[3Srb36gRZN{[Xl?	MnnFOVAwOTBy4pEJxtVO	NWTzXW5TPDhiaB?=	NHi0O3lFVVOR	M4nNRpJm\HWlZYOgZY5wcWurczDy[ZNqe3SjbnPl	NYm4Opg{OjV{MU[1NlI>
MeWo	M4jnT2Z2dmO2aX;uJGF{e2G7	M2qySFUxNzFyMPMAjeK2VQ>?	MUC0PEBp	NV;SPXhTTE2VTx?=	NVTEUld1emWmdXPld{Bidm:ra3nzJJJme2m\|dHHuZ4U>	NGPiVlUzPTJzNkWyNi=>
SK-MEL-5	MUHGeY5kfGmxbjDBd5NigQ>?	MorHOVAwOTBy4pEJxtVO	NYHGdIJnPDhiaB?=	M3zXVGROW09?	MWny[YR2[2W\|IHHuc4lscXNicnXzbZN1[W6lZR?=	MoPjNlUzOTZ3MkK=
SK-MEL-2	NHrpeWZHfW6ldHnvckBCe3OjeR?=	MVW1NE8yODEkgJpCuW0>	M{jGU\|Q5KGh?	NHr5eFZFVVOR	NFXxe5hz\WS3Y3XzJIFvd2mtaYOgdoV{cXO2YX7j[S=>	MljmNlUzOTZ3MkK=
B16-F0	M2r3[GZ2dmO2aX;uJGF{e2G7	NYTWTnhRPTBxMUCw5qCKyrWP	NYS3V4FiPDhiaB?=	NX3ZeXBITE2VTx?=	NFLWcZdz\WS3Y3XzJIFvd2mtaYOgdoV{cXO2YX7j[S=>	M4TuXVI2OjF4NUKy
TRPM2/HEK	MlrPSpVv[3Srb36gRZN{[Xl?	Mni2NE4y6oDVMkZCpOK2VQ>?	M4\OflE2yqCvaX6=	MVzEUXNQ	NHTUXplz\WS3Y3XzJGgzVzJvaX7keYNm\CCFYUKrbY5kemWjc3WgbY4h[SClb37j[Y51emG2aX;uMYRmeGWwZHXueEBu[W6wZYKsJIFv\CC2aHWgTWM2OMLidnHseYUhf2G\|IEGuO:KhyrWP	NGLMZ\|MzPTF5OUW3OC=>
U937	NXT3[YdzTnWwY4Tpc44hSXO\|YYm=	Ml\QNE4y6oDVMkZCpOK2VQ>?	NGG3RWoyPcLibXnu	NYeycHdxTE2VTx?=	Mlr4doVlfWOnczDINm8zNWmwZIXj[YQhS2F{K3nuZ5Jm[XOnIHnuJIEh[2:wY3XueJJifGmxbj3k[ZBmdmSnboSgcYFvdmW{LDDhcoQhfGinIFnDOVDDqH[jbIXlJJdieyByLkVCpOK2VQ>?	M2Xo[VI2OTd7NUe0
TRPM2/HEK	MUTGeY5kfGmxbjDBd5NigQ>?	NYC2WldTOTEEoNM1US=>	MljYOFDDqG2rbh?=	M3jQV2ROW09?	M2e0fpJm\HWlZYOgWHJRVTJiYXP0bZZifGmxbjDleoVvKGG2IHjp[4gh[2:wY3XueJJifGmxboOgc4YhUDKRMh?=	M1LRXlI2OTd7NUe0
GL37	NUC4bZdNS2WubDDWbYFjcWyrdImgRZN{[Xl?	NHjF[20xNTFywrFCuW0>	NU\kU3VmPDhiaB?=		M{PxcZN2eHC{ZYPz[ZMhVGFiZYjwdoV{e2mxbh?=	M4HGUFI1QTl7NkW3
NRK-52E	MVfGeY5kfGmxbjDBd5NigQ>?	MW[xxsDDvU1?	MYKxNEBucW5?		M33uWYJtd2OtczD0bIUhe3SrbYXsZZRwenliZX\m[YN1KG:oIFHu[{BKUSCxbjDQZZguOiCneIDy[ZN{cW:wwrC=	M{TEcFI1PzFyNEKz
NRK-52E	NIXQe4pHfW6ldHnvckBCe3OjeR?=	NIDx[3MyyqEEtV2=	MorxNVAhdWmw		M1nzWoJtd2OtczDBcochUUliaX7keYNm\CCFREK0JIV5eHKnc4Ppc44>	Mn;sNlQ4OTB2MkO=
HSC	Mnn4SpVv[3Srb36gRZN{[Xl?	Mo[zNlAh\|ryP	MVSxJIg>		NEC4UIJi[nKxZ3H0[ZMhfGinIHTp[oZmemWwdHnhcEBm\m[nY4TzJI9nKGyncITpckBweiCDR1Xz	MX6yOFYyPDF7OR?=
EJ	M{TJPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1;hSVUxNzhyIN88US=>	MVmyOE81QC95MjDo		MVjpcohq[mm2czDj[YxtKGe{b4f0bEBqdiCkb4ToJJRqdWViYX7kJIRwe2ViZHXw[Y5l\W62IH3hco5meg>?	NHW1SZUzPDV6N{C0PS=>
EJ	NULiZ4F7T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M4jFPVUxNzhyIN88US=>	NF;6dGg1QCCq		MnnzZ4F2e2W\|IGOtdIhie2ViYYLy[ZN1	NX;pR5lnOjR3OEewOFk>
EJ	MkPiSpVv[3Srb36gRZN{[Xl?	MknkOVAwQDBizszN	NXv0cFhTPDhiaB?=		NEDueXVld3ewcnXneYxifGW\|IHOtUZlkNCCleXPsbY5FOSxic4Xyeol3cW5iYX7kJHZGT0ZiZYjwdoV{e2mxboO=	NXS3cnVjOjR3OEewOFk>
HepG2	NUXDTZN6TnWwY4Tpc44hSXO\|YYm=	NFXLOWM2OC13MECg{txO	MX62NOKhdWmw		M3nMOIlvcGmkaYTzJJRp\SCLTD22MYlv\HWlZXSgdIhwe3Cqb4L5cIF1cW:wIH;mJHNVSVRzIDjUfZI4ODVrIHHu[EBUXEGWMzCoWJlzPzB3KTDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?=	NXjLVGxPOjR{NEKwOFY>
SGC7901	MXjD[YxtKF[rYXLpcIl1gSCDc4PhfS=>	M4rQUVAuOTByIN88US=>	MUKyOE81QC95MjDo		MoDxZ4F2e2W\|IHGgd4lodmmoaXPhcpQhemWmdXP0bY9vKGmwIHPlcIwhfmmjYnnsbZR6KGSxc3Wt[IVx\W6mZX70cJkh[nW2IH7veEB1cW2nLXTldIVv\GWwdHz5	MljkNlQyPTF{NUW=
AGS	NGL0dllE\WyuIG\pZYJqdGm2eTDBd5NigQ>?	MkfuNE0yODBizszN	NUH4TmtmOjRxNEivO\|IhcA>?		Mo\RZ4F2e2W\|IHGgd4lodmmoaXPhcpQhemWmdXP0bY9vKGmwIHPlcIwhfmmjYnnsbZR6KGSxc3Wt[IVx\W6mZX70cJkh[nW2IH7veEB1cW2nLXTldIVv\GWwdHz5	NH;Zd\|kzPDF3MUK1OS=>
SGC7901	M17DSWZ2dmO2aX;uJGF{e2G7	M3v1SVUxKM7:TR?=	NHXvcoMzPC92OD:3NkBp		NX;iUG5PfGinIHzleoVteyCxZjDwTmFMOiCkZXfhckB1dyCmZXPsbY5mKGG2IEK0JIhzNCCjbnSgdoVjd3WwZHXkJIF1KDd{IHjyxsA>	MlfuNlQyPTF{NUW=
AGS	NGnsVnBHfW6ldHnvckBCe3OjeR?=	NE\TbYY2OCEQvF2=	M2\LTlI1NzR6L{eyJIg>		M3nIXpRp\SCuZY\lcJMhd2ZicFrBT\|Ih[mWpYX6geI8h\GWlbHnu[UBifCB{NDDodkwh[W6mIILlZo92dmSnZDDheEA4OiCqctMg	Ml;WNlQyPTF{NUW=
SGC7901	NW\VN2dkTnWwY4Tpc44hSXO\|YYm=	MUi1NEDPxE1?	NHrZc5czPC92OD:3NkBp		MmGzeIhmKGO7dH;wcIF{dWmlIHzvZ4FtcXqjdHnvckBw\iCySlHLNkApUkGNMjDwbI9{eGixconsZZRm\CCjdDDy[ZNq\HWnczDUfZIyODB5IHHu[EBVgXJzMEC4LUBl\WO{ZXHz[YQh[W[2ZYKgRWc1QTBidILlZZRu\W62IH\vdkAzPCCjbnSgOFghcHJuIHL1eEB{fGG{dHXkJJRwKHKnYn;1coQh[XRiN{KgbJI>	MWiyOFE2OTJ3NR?=
AGS	NF;pU2lHfW6ldHnvckBCe3OjeR?=	MXm1NEDPxE1?	NHOyRmkzPC92OD:3NkBp		NX3VfI5nfGinIHP5eI9xdGG\|bXnjJIxw[2GuaYrheIlwdiCxZjDwTmFMOiBqSlHLNkBxcG:\|cHjvdplt[XSnZDDheEBz\XOrZIXld{BVgXJzMEC3JIFv\CCWeYKxNFA5MSCmZXPy[YF{\WRiYX\0[ZIhSUd2OUCgeJJm[XSvZX70JIZweiB{NDDhcoQhPDhiaIKsJIJ2fCC\|dHHyeIVlKHSxIILlZo92dmRiYYSgO\|IhcHJ?	MUCyOFE2OTJ3NR?=
MC3T3-E1	M2PvU2Z2dmO2aX;uJGF{e2G7	NUO0VohsPTBizszN	M2jub\|QhcA>?		MlK5bY5pcWKrdIOgTHNGNWmwZIXj[YQhSk2SNzDhcoQhT0iUIIDyc5RmcW5iZYjwdoV{e2mxbtMg	NEDTbnczOzh5N{ezOC=>
7TD1-DXM	NIH3TWZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MX6xNEDPxE1?	Mon2O\|IhcA>?	NVHZXXZrTE2VTx?=	NIfpTnJqdmirYnn0d{Bk\WyuIHfyc5d1cA>?	M4XVZlI{QDdzMUW5
7TD1-WD-90	MoHFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MVmxNEDPxE1?	MYK3NkBp	MlfuSG1UVw>?	NUXCcldlcW6qaXLpeJMh[2WubDDndo94fGh?	NY\JdGZMOjN6N{GxOVk>
7TD1-DXM	NFnX[3VCeG:ydH;zbZMhSXO\|YYm=	NX\COI5uPTBizszN	Mk\lOFghcA>?	MYnEUXNQ	NVHKNJgxcW6mdXPld{BieG:ydH;zbZM>	NHP4V5AzOzh5MUG1PS=>
7TD1-WD-90	NEfsR4xCeG:ydH;zbZMhSXO\|YYm=	NHzoXHM2OCEQvF2=	MXW0PEBp	M1XaV2ROW09?	MmL1bY5lfWOnczDhdI9xfG:\|aYO=	NEmxe3YzOzh5MUG1PS=>
7TD1-WD-90	MkHrSpVv[3Srb36gRZN{[Xl?	MmixOVAh\|ryP	M{PKR\|YhcA>?	M4HCOmROW09?	NEDuPG9{cWewaX\pZ4FvfGy7IHnubIljcXS\|IITo[UBxcG:\|cHjvdplt[XSrb36gc4YhUkGNMjDhcoQheGixc4Doc5J6dGG2aX;uJI9nKFOWQWSz	M3\uc\|I{QDdzMUW5
HepG2	M2LhR2Z2dmO2aX;uJGF{e2G7	MlHZNVAxKM7:TR?=	NXmzOINoOTJxMkSgbC=>		NGTFVlRqdmirYnn0d{BUXEGWMzD0fZJwe2mwZTDwbI9{eGixconsZZRqd25?	MYmyN\|g{PjRyMB?=
RAW264.7	NEXjOoNHfW6ldHnvckBCe3OjeR?=	MoTLOVDDqM7:TdMg	MXGyOE81QCCq		NXHVdJZbe3WycILld5NmeyCUQV7LUE1qdmS3Y3XkJI9{fGWxY3zhd5Rw\2WwZYPpdy=>	NUXiPYUyOjN4NkWwNVg>
RAW264.7	MlXpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MWiwMVUxyqEQvF5CpC=>	NUnvRW9pPDkEoHi=		M1TEfIlvcGmkaYTzJINmdGxiZ4Lve5RpKGSxc3Wt[IVx\W6mZX70cJk>	MVOyN\|Y3PTBzOB?=
RAW264.7	M3PpZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M4KxPVAuPTEEoN88UeKh	M3\zbFQ5yqCq		MoXEZ4F2e2W\|IHHuJIFzemW\|dDDv[kBTSVd{NkSuO{Bk\WyuczDheEB1cGViR{CvS\|EheGijc3Wgc4YhfGinIHPlcIwh[3mlbHW=	M1LMO\|I{PjZ3MEG4
RAW264.7	NELNWXBHfW6ldHnvckBCe3OjeR?=	MV61NOKh\|ryP	MnXNNlQwPDhiaB?=		M2G2eIlvcGmkaYTzJHJCVkuOLXnu[JVk\WRiTl\BWIMyKGW6cILld5Nqd25iYX7kJJBpd3OyaH;yfYxifGmxbjDv[kBU\XJ5MkfTWGFVOw>?	MlvENlM3PjVyMUi=
A549	NH;W[YdHfW6ldHnvckBCe3OjeR?=	NWHVV2E4OjBxNECg{txO	MViyNEBp		NIq5bJEzOCEQvF2gRWc1QTBic4XwdJJme3OnczD0bIUhemGmaXH0bY9vNWmwZIXj[YQhcW64YYPpc44hd2ZiQUW0PUBk\Wyucx?=	M2nSblI{PjJyMUmx
A549	NUj3fFJ5TnWwY4Tpc44hSXO\|YYm=	MXmxNE8zOC92MDFOwG0>	MXKyOEBp		NHTLcoJ{fXCycnXzd4V{KHSqZTDyZYRq[XSrb36tbY5lfWOnZDDlcIV3[XSrb36gc4YhXkWJRtMg	NUXRN21sOjN4MkCxPVE>
HUVECs	MV7D[YxtKF[rYXLpcIl1gSCDc4PhfS=>	Mn7NNlAhyrWP	MV[0JIg>		NFTEbVhifHSnboXheIV{KEh{T{KtbY5lfWOnZDDj[YxtKHOqcnnub4Fo\SCjbnSgbY1xem:4ZXSgeIhmKGG2dHHjbI1mdnRicnH0[UBw\iC2aHWgZ4VtdHN?	NV3OTW1xOjN2OEO5OFY>
HUVECs	M{GySmFxd3C2b4Ppd{BCe3OjeR?=	NFT2XmgzOCEEtV2=	NXPScWd6PCCq		NWi2dmQ3e2mpbnnmbYNidnSueTDk[YNz\WG\|ZYOgeIhmKGOnbHygZZBweHSxdHnjJIlv\GW6	NY\YVFFoOjN2OEO5OFY>
BV-2	NFf3bppHfW6ldHnvckBCe3OjeR?=	NWPIfnF1OjBiwsXN	MoewNVYhcA>?		NEfpNI9qdmirYnn0d{BNWFNvaX7keYNm\CCVVFHUNUBxcG:\|cHjvdplt[XSrb36ge4l1cCCjbH3vd5Qh[2:vcHzleIVtgSCmaX3pcol{cGWmIHnOU3Mh\XiycnXzd4lwdg>?	MoHCNlMzOzZ\|N{C=
NRK-52E	NHy2[nBHfW6ldHnvckBCe3OjeR?=	NWT1XVE4PcLizszN	M3:0dFMxyqCvaX6=		MV\heJRmdnWjdHXzJGFv\y1qMfMAl\|cqNWmwaHnibZRm\CCWR1[t{tIyKG2UTlGgZZQhOTcEoHlCpC=>	NWm3dnN6OjNzN{S3OVc>
SW620	MYHGeY5kfGmxbjDBd5NigQ>?	M4LENlIxKML3TR?=	M{TpV\|EwPiCq		NYnHU3dzcW6qaXLpeJMheC2VVFHUN{Bi[3SrdnH0bY9v	M1fOeFI{OTFyNkK1
RPE	M3Tzc2Z2dmO2aX;uJGF{e2G7	M3T0VlMxKML3TdMg	MVKzJIg>		MWfpcohq[mm2czD0bIUhcW6mdXP0bY9vKG:oIICtV3RCXDNiZYjwdoV{e2mxbh?=	Mn;XNlMxQTRyNke=
SW1116	NUn1VJRITnWwY4Tpc44hSXO\|YYm=	NX[1TmZSOTByINM1UeKh	M2Hq[VI1NzR6L{eyJIg>		NXnySVdG\GWlcnXhd4V{KHSqZTDlfJBz\XO\|aX;uJI9nKEqDS{KgZY5lKHCMQVuyJJRqdWVvZHXw[Y5l\W62bIm=	M{DoXFIzODVyN{mw
HT29	MUPGeY5kfGmxbjDBd5NigQ>?	M1TJNVExOCEEtV5CpC=>	M4HYTFI1NzR6L{eyJIg>		Mkjs[IVkemWjc3XzJJRp\SCneIDy[ZN{cW:wIH;mJGpCUzJiYX7kJJBLSUt{IITpcYUu\GWyZX7k[Y51dHl?	M2nZdFIzODVyN{mw
SW1116	M4nTNmZ2dmO2aX;uJGF{e2G7	NE[z[FYyODBiwsXNxsA>	NIK1epIzPC92OD:3NkBp		NY\SboNl\GWlcnXhd4V{KHSqZTDwV3RCXDNibHX2[Yx{KGmwIHGgeIlu\S2mZYDlcoRmdnRibXHucoVzyqB?	MV6yNlA2ODd7MB?=
HT29	Mk\LSpVv[3Srb36gRZN{[Xl?	NFTYfVcyODBiwsXNxsA>	Mmi5NlQwPDhxN{KgbC=>		MnPL[IVkemWjc3XzJJRp\SCyU2TBWFMhdGW4ZXzzJIlvKGFidHnt[U1l\XCnbnTlcpQhdWGwbnXyxsA>	NWrTOph{OjJyNUC3PVA>
ARPE-19	NYjpSVZJTnWwY4Tpc44hSXO\|YYm=	M3nZV\|XDqM7:TR?=	MkO4N\|DDqG2rbh?=		NYHWTopwcW6qaXLpeJMhUkGNMjDwbI9{eGixcnnsZZRqd25?	MojWNlE3OjB7NkO=
HSC-T6	Ml;iRZBweHSxc3nzJGF{e2G7	MVKxNOKh\|ryP	MX2yxsBpyqB?		NHvqXGJqdmirYnn0d{B1cGViYYDvdJRwe2m\|IH;mJGhUSy2WNjDj[YxteyCrbnT1Z4VlKGK7IFPESS=>	NFzTWVIzOTN7Nkm5PC=>
HSC-T6	MVrGeY5kfGmxbjDBd5NigQ>?	MkXPNVDDqM7:TR?=	MmXoNuKhcMLi		NWmyZ5h7cW6qaXLpeJMhfGinIHX4dJJme3Orb37zJI9nKHC\LWPURXQyKGGwZDDCZYQhcW6mdXPl[EBjgSCFRFW=	MX6yNVM6Pjl7OB?=
Hep-2	NWTwUXFtT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NVP4RnU1OjVvMUCwJO69VQ>?	NYLDWVhuOjRxNEivO\|IhcA>?		M17ZeolvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHLveIghfGmvZTDhcoQh\G:\|ZTDk[ZBmdmSnboSgcYFvdmW{	NYm0dJJtOjF\|MEm0PFE>
Hep-2	NYLVSZE1SXCxcITvd4l{KEG\|c3H5	MmrUOVAh\|ryP	NEHhRW8zPC92OD:3NkBp		M175b4lv\HWlZYOgZ4VtdCCjcH;weI9{cXNidHnt[UBl\XCnbnTlcpRtgQ>?	NEP6UFczOTNyOUS4NS=>
Hep-2	NUH2SJJjTnWwY4Tpc44hSXO\|YYm=	MX[1NEDPxE1?	MnLkNlQwPDhxN{KgbC=>		M2TicIlvcGmkaYTzJGcyKHSxIGOgZ4VtdCCleXPs[UB1emGwc3n0bY9vKGGwZDDpcoR2[2W\|IFexJINmdGxiY4njcIUh[XK{ZYP0	NYe1UHJsOjF\|MEm0PFE>
Hep-2	NVfVTWtbTnWwY4Tpc44hSXO\|YYm=	MVi1NEDPxE1?	Moj2NlQwPDhxN{KgbC=>		MUPkc5dvemWpdXzheIV{KHSqZTDTWGFVOyxicD3TWGFVOyCjbnSgd5Vzfmm4aX6gdJJwfGWrbjDs[ZZmdHN?	NFXjeGUzOTNyOUS4NS=>
KF8	M1HaTGZ2dmO2aX;uJGF{e2G7	MlPLNVDDqM7:TdMg	NGnleHUyyqCq	MUPEUXNQyqB?	NEXa[lhqdmirYnn0d{BKVC1\|Mz3pcoR2[2WmIF7GMe67SiCjY4TpeoF1cW:w	M{jmPVIxQTRyMES1
KF8	Mn3CSpVv[3Srb36gRZN{[Xl?	MmTKNVDDqM7:TdMg	NUK3bllOOcLiaNMg	M4TxRmROW00EoB?=	NI\4XlRqdmirYnn0d{BKVC1\|Mz3pcoR2[2WmIFpOvmLPuSCmZXfyZYRifGmxbjDhcoQhVkZvzsrCJIFkfGm4YYTpc44>	Mkf6NlA6PDByNEW=
HEL	M37PRmZ2dmO2aX;uJGF{e2G7	NVPsemhbOTBywrFOwG0>	MVuxNk04OiCq		M4TaeolvcGmkaYTzJJRp\SCuZY\lcEBw\iCyLVrBT\|ItKEqDS{K=	NXjpW3BiOjB4MkGwOlE>
HEL	NYL6c5JCT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NYDzV5U{OTBywrFOwG0>	MkfWNE02KGR?		MVLy[YR2[2W\|IHfyc5d1cCCxZjDKRWszXjZzN1[t[ZhxemW\|c3nu[{BJTUxiY3XscJM>	NH;PV\|UzODZ{MUC2NS=>
A-172	M4KxSmZ2dmO2aX;uJGF{e2G7	M{\BeFUxNzFyMNMg{txO	NEHrWJM1QCCq		MUny[YR2[2W\|IITo[UBt\X[nbIOgc4Yh[2:wc4TpeJV1cX[nbImgZYN1cX[jdHXkJHNVSVR\|IHnuJIEhfGmvZT3k[ZBmdmSnboSgZY5lKGSxc3Wt[IVx\W6mZX70JIZie2irb36=	M2fFUVIxPTh7NUK1
MZ-18	NVzuNo9ZTnWwY4Tpc44hSXO\|YYm=	MYm1NE8yODEEoN88US=>	NUGzdmdNPDhiaB?=		NWLHbo5YemWmdXPld{B1cGVibHX2[Yx{KG:oIHPvcpN1cXS3dHn2[Yx6KGGldHn2ZZRm\CCVVFHUN{BqdiCjIITpcYUu\GWyZX7k[Y51KGGwZDDkc5NmNWSncHXu[IVvfCCoYYPobY9v	NWnkNmtkOjB3OEm1NlU>
MZ-54	NFTTc\|RHfW6ldHnvckBCe3OjeR?=	NXTUV2NZPTBxMUCwxsDPxE1?	MkPYOFghcA>?		NY\sXGdIemWmdXPld{B1cGVibHX2[Yx{KG:oIHPvcpN1cXS3dHn2[Yx6KGGldHn2ZZRm\CCVVFHUN{BqdiCjIITpcYUu\GWyZX7k[Y51KGGwZDDkc5NmNWSncHXu[IVvfCCoYYPobY9v	MUKyNFU5QTV{NR?=
MZ-256	M2PxUGZ2dmO2aX;uJGF{e2G7	NIXOUI42OC9zMEFCpO69VQ>?	MVS0PEBp		M1rTcpJm\HWlZYOgeIhmKGyndnXsd{Bw\iClb37zeIl1fXSrdnXsfUBi[3SrdnH0[YQhW1SDVEOgbY4h[SC2aX3lMYRmeGWwZHXueEBidmRiZH;z[U1l\XCnbnTlcpQh\mG\|aHnvci=>	MXSyNFU5QTV{NR?=
MZ-304	M1LE[2Z2dmO2aX;uJGF{e2G7	MW[1NE8yODEEoN88US=>	NX7qdIdWPDhiaB?=		MXLy[YR2[2W\|IITo[UBt\X[nbIOgc4Yh[2:wc4TpeJV1cX[nbImgZYN1cX[jdHXkJHNVSVR\|IHnuJIEhfGmvZT3k[ZBmdmSnboSgZY5lKGSxc3Wt[IVx\W6mZX70JIZie2irb36=	NHK4dWMzODV6OUWyOS=>
A-172	NUHOdVdDT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3nZWlUxNzFyMNMg{txO	M3PZdFQ5KGh?		NWDDUFVzdGWjZIOgeI8h[SC\|dHH0bZN1cWOjbHz5JJNq\26rZnnjZY51KHKnZIXjeIlwdiCxZjDj[YxtKHC{b3zp[oVz[XSrb36gc5ZmeiCjIITpcYUheGW{aX;kJI9nKDR6wrDo	Mnr2NlA2QDl3MkW=
MZ-18	MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3m2WFUxNzFyMNMg{txO	MmPuOFghcA>?		NX3nPG95dGWjZIOgeI8h[SC\|dHH0bZN1cWOjbHz5JJNq\26rZnnjZY51KHKnZIXjeIlwdiCxZjDj[YxtKHC{b3zp[oVz[XSrb36gc5ZmeiCjIITpcYUheGW{aX;kJI9nKDR6wrDo	MXOyNFU5QTV{NR?=
MZ-54	NF:0bXRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MXW1NE8yODEEoN88US=>	MYG0PEBp		NF;3epRt\WGmczD0c{BiKHO2YYTpd5Rq[2GubImgd4lodmmoaXPhcpQhemWmdXP0bY9vKG:oIHPlcIwheHKxbHnm[ZJifGmxbjDveoVzKGFidHnt[UBx\XKrb3Sgc4YhPDkEoHi=	M4rqVlIxPTh7NUK1
MZ-256	NH24TWFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3;uc\|UxNzFyMNMg{txO	M2HINlQ5KGh?		NF;Ib5pt\WGmczD0c{BiKHO2YYTpd5Rq[2GubImgd4lodmmoaXPhcpQhemWmdXP0bY9vKG:oIHPlcIwheHKxbHnm[ZJifGmxbjDveoVzKGFidHnt[UBx\XKrb3Sgc4YhPDkEoHi=	MXSyNFU5QTV{NR?=
MZ-304	NGjlbJNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NIDoc5U2OC9zMEFCpO69VQ>?	M33LO\|Q5KGh?		NITheZBt\WGmczD0c{BiKHO2YYTpd5Rq[2GubImgd4lodmmoaXPhcpQhemWmdXP0bY9vKG:oIHPlcIwheHKxbHnm[ZJifGmxbjDveoVzKGFidHnt[UBx\XKrb3Sgc4YhPDkEoHi=	NWn1[ZR1OjB3OEm1NlU>
A-172	MYnGeY5kfGmxbjDBd5NigQ>?	NWKzeWRoPTBxMUCwxsDPxE1?	M4f6dVQ5KGh?		M1vacIlvcGmkaYTzJI1q\3KjdHnvci=>	M4my[\|IxPTh7NUK1
MZ-18	Moe2SpVv[3Srb36gRZN{[Xl?	NVT5WYJWPTBxMUCwxsDPxE1?	Ml7TOFghcA>?		NFLXSnFqdmirYnn0d{BucWe{YYTpc44>	M4fZPVIxPTh7NUK1
MZ-54	NEnoO21HfW6ldHnvckBCe3OjeR?=	NV;PWHRuPTBxMUCwxsDPxE1?	M2q0fVQ5KGh?		M4TDNIlvcGmkaYTzJI1q\3KjdHnvci=>	NH21R20zODV6OUWyOS=>
MZ-256	MWTGeY5kfGmxbjDBd5NigQ>?	NULiSY9UPTBxMUCwxsDPxE1?	MVy0PEBp		MYjpcohq[mm2czDtbYdz[XSrb36=	M4WwWFIxPTh7NUK1
MZ-304	NYTXcIZuTnWwY4Tpc44hSXO\|YYm=	MWG1NE8yODEEoN88US=>	MVi0PEBp		MUjpcohq[mm2czDtbYdz[XSrb36=	NVjkdVlROjB3OEm1NlU>
A-172	NX\yOm1OTnWwY4Tpc44hSXO\|YYm=	M3XpeFExOMLizszN	MXK0PEBp		M4HOUYlvcGmkaYTzJIlvfmG\|aX;u	Mk\vNlA2QDl3MkW=
MZ-18	M1nrdmZ2dmO2aX;uJGF{e2G7	M2f4WFExOMLizszN	MW[0PEBp		MXrpcohq[mm2czDpcpZie2mxbh?=	NGm4bY4zODV6OUWyOS=>
MZ-54	MkH6SpVv[3Srb36gRZN{[Xl?	M2XYclExOMLizszN	MlznOFghcA>?		NUfab3Y4cW6qaXLpeJMhcW64YYPpc44>	M1;oe\|IxPTh7NUK1
MZ-256	MUHGeY5kfGmxbjDBd5NigQ>?	MlrTNVAxyqEQvF2=	MXm0PEBp		NXvMV\|V4cW6qaXLpeJMhcW64YYPpc44>	NX7OdnhnOjB3OEm1NlU>
MZ-304	M{Dh[2Z2dmO2aX;uJGF{e2G7	NXfTc2RMOTBywrFOwG0>	NX\wbo0{PDhiaB?=		M1\uXYlvcGmkaYTzJIlvfmG\|aX;u	MofyNlA2QDl3MkW=
A-172	MnzZSpVv[3Srb36gRZN{[Xl?	NEK1XpI2OC9zMEFCpO69VQ>?	NWC4OphvPDhiaB?=		MWHy[YR2[2W\|IITyZY5{[3KrcITpc44hd2ZiTV3QJIdmdmW\|IHHu[EBz\WS3Y3XzJIVvgnmvYYTpZ{Bi[3Srdnn0fUBw\iCPTWDz	M{LmSVIxPTh7NUK1
MZ-18	M4WxbmZ2dmO2aX;uJGF{e2G7	NEHBO3M2OC9zMEFCpO69VQ>?	NGOxd5U1QCCq		MmnldoVlfWOnczD0doFve2O{aYD0bY9vKG:oIF3NVEBo\W6nczDhcoQhemWmdXPld{Bmdnq7bXH0bYMh[WO2aY\peJkhd2ZiTV3Qdy=>	M{TFWVIxPTh7NUK1
MZ-54	NUjpZVQ4TnWwY4Tpc44hSXO\|YYm=	NInEd3E2OC9zMEFCpO69VQ>?	MVy0PEBp		MlvjdoVlfWOnczD0doFve2O{aYD0bY9vKG:oIF3NVEBo\W6nczDhcoQhemWmdXPld{Bmdnq7bXH0bYMh[WO2aY\peJkhd2ZiTV3Qdy=>	M2jTWVIxPTh7NUK1
MZ-256	NInsV5ZHfW6ldHnvckBCe3OjeR?=	M4TmTFUxNzFyMNMg{txO	Mlj2OFghcA>?		NInydIRz\WS3Y3XzJJRz[W6\|Y4LpdJRqd25ib3[gUW1RKGenbnXzJIFv\CC{ZXT1Z4V{KGWweontZZRq[yCjY4Tpeol1gSCxZjDNUXB{	NH3Qe5czODV6OUWyOS=>
MZ-304	NGj2TmhHfW6ldHnvckBCe3OjeR?=	NEXDUXo2OC9zMEFCpO69VQ>?	M1u3fFQ5KGh?		NFjST4Vz\WS3Y3XzJJRz[W6\|Y4LpdJRqd25ib3[gUW1RKGenbnXzJIFv\CC{ZXT1Z4V{KGWweontZZRq[yCjY4Tpeol1gSCxZjDNUXB{	MlviNlA2QDl3MkW=
SW1990	NVfiPVVFT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3vP[FIxKM7:TR?=	NUPzRlJwOjRxNEivO\|IhcA>?		MnXEbY5pcWKrdIOgZ4VtdCCpcn;3eIghfGmvZTDk[ZBmdmSnboTsfS=>	NIDt[m4zODR6Mki1PC=>
SW1990	NE\JbVhHfW6ldHnvckBCe3OjeR?=	NYPDeFRqOjBizszN	NGjU[G4zPCCq		Mnvl[IVkemWjc3XzJJRp\SCneIDy[ZN{cW:wIH;mJG1OWC1{IHHu[EBXTUeIIH3SUmF{	Mo\nNlA1QDJ6NUi=
SW1990	M1XrWGZ2dmO2aX;uJGF{e2G7	M4m3SlIxKM7:TR?=	MYKyOEBp		MUjk[YNz\WG\|ZYOgeIhmKGmwdHXud4l1gSCxZjDwMXN1[XR\|IHX4dJJme3Orb36=	M3vkVlIxPDh{OEW4
SW1990	Ml;CTY53[XOrb36gRZN{[Xl?	M4nlXlIxKM7:TR?=	M{fRUVI1KGh?		NIfMeJlz\WS3Y3XzJIlvfmG\|aX;uJI9nKFOZMUm5NEBk\Wyuc9Mg	M1;vZ\|IxPDh{OEW4
THP1	NV2xW441TnWwY4Tpc44hSXO\|YYm=	M3LPbVExKHWP	NF;uWWU{OCCvaX9CpC=>		MWfpcohq[mm2czDTWGFVOyC2eYLvd4lv\SCyaH;zdIhwenmuYYTpc44h[nlib4\ldkA3OCV?	MUWyNFM6OzZ7MB?=
BMMC	NULtbm1ZTnWwY4Tpc44hSXO\|YYm=	MlPTNE0yOCEQvF2=	NI\XNpkyPcLibXnu		NWXJeHBIcW6qaXLpeJMhVFSFNNMgdoVt\WG\|ZTDpckBiKGSxc3Wt[IVx\W6mZX70JIZie2irb36ge4l1cCCwZXHyJINwdXCuZYTlJIlvcGmkaYTpc44h[XRiY3;uZ4VvfHKjdHnvcpMh6qn-MUFCpO69VQ>?	M4nlO\|E6QDN3OES1
A549	M4PBUGZ2dmO2aX;uJGF{e2G7	M33lRlE2KM7:bR?=	NFrw[\|cyKGh?		Mo[4bY5pcWKrdIOgeIhmKHCqb4PwbI9zgWyjdHnvckBw\iCVVFHUNUBwdiC2eYLvd4lv\SB5MEGge4F{KGSndHXjeIVlKDF3IH3pckBi\nSncjDTVGUhSiC2cnXheI1mdnR?	M{jDVVE6QDBzNk[1
OVCAR-3	NGDCO45HfW6ldHnvckBCe3OjeR?=	NWXIfFJEOTBidV2=	NH6wbIwyKGh?		NUHPTGc3cW6qaXLpeJMhVFCDLXnu[JVk\WRiU2TBWFMheGixc4Doc5J6dGG2aX;u	NFnDeZMyQTZ2N{O2Ny=>
PA-1	NX\nT\|l1TnWwY4Tpc44hSXO\|YYm=	Mn7hNVAhfU1?	NGT2WY4yKGh?		NIewR5NqdmirYnn0d{BNWEFvaX7keYNm\CCVVFHUN{BxcG:\|cHjvdplt[XSrb36=	NInzSnUyQTZ2N{O2Ny=>
OVCAR-3	NUX1W5JZTnWwY4Tpc44hSXO\|YYm=	M{T0UVExKHWP	NETSfoEyKGh?		M1nYRolvcGmkaYTzJEBNWEFvaX7keYNm\CCxdnHybYFvKGOjbnPldkBk\WyuIH3veIltcXS7	Mn;LNVk3PDd\|NkO=
PA-1	MnTuSpVv[3Srb36gRZN{[Xl?	NYHtN2c4OTBidV2=	MlTNNUBp		M3S3[4lvcGmkaYTzJEBNWEFvaX7keYNm\CCxdnHybYFvKGOjbnPldkBk\WyuIH3veIltcXS7	NUHqOm1YOTl4NEezOlM>
Jurkat	MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MoHtOVAh\|ryP	NVXHSYlkOjRxNEivO\|IhcA>?		NInOZ2hmdmijbnPld{BVWkGLTD3pcoR2[2W\|IHPlcIwh\3Kxd4ToJIlvcGmkaYTpc44>	NXjnU3k2OTl3NkS4PVE>
SUPT1	M2rvfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NVzWPJR2PTBizszN	MoLCNlQwPDhxN{KgbC=>		NVPqb5lj\W6qYX7j[ZMhXFKDSVytbY5lfWOnczDj[YxtKGe{b4f0bEBqdmirYnn0bY9v	Mn\oNVk2PjR6OUG=
Jurkat	M3WwXmFxd3C2b4Ppd{BCe3OjeR?=	MVW1NEDPxE1?	NWnhZlhbOjRxNEigbC=>		MkLi[Y5p[W6lZYOgWHJCUUxvaX7keYNmeyClZXzsJIFxd3C2b4Ppdy=>	MoLPNVk2PjR6OUG=
SUPT1	NYSxN\|h5SXCxcITvd4l{KEG\|c3H5	MkTOOVAh\|ryP	M1;2PVI1NzR6IHi=		MX\lcohidmOnczDUVmFKVC2rbnT1Z4V{KGOnbHygZZBweHSxc3nz	MYexPVU3PDh7MR?=

... Click to View More Cell Line Experimental Data

In vivo

Administration of AG-490 drastically reduces the numbers of CD45⁺ and HLA-DR⁺ cells from 48 % and 46% in bone marrow of untreated mice, as well as 38% and 22% in the spleen of untreated mice to undetectale levels. ^[2] In vivo administration of AG-490 causes murine myeloma tumor cell apoptosis but does not inhibit IL-12-mediated macrophage activation and IFN-γ production by lymphocytes. ^[6] Consistent with the in vitro blocking of JAK2 V617F mutant activity, AG-490 treatment at 0.5 mg/day for 10 days effectively inhibits JAK2 V617F mutant-induced tumorigenesis and tumor cell invasion in nude mice. ^[8] Combined therapy with AG-490 and IL-12 induces greater antitumor effects than either agent alone in a murine myeloma tumor model. ^[6]

Protocol

Kinase Assay: ^[1]	- Collapse In vitro kinase autophosphorylation: AG-490 is dissolved in DMSO 10%-H₂O-ethanol 45%. Crude membrane extracts (0.125 μg/mL) are preactivated with EGF (20 nM) in 50 mM HEPES buffer, pH 7.6, and 125 mM NaCl, for 15 minutes at 4 °C. Autophosphorylation activity of EGFR or ErbB2 kinase is assayed at 4 °C for 30 seconds in V-shaped 96-well plates. Membrane extracts (8 μL) are added to each well containing reaction mixture (12 μL, 50mM, HEPES, pH 7.4,125 mM NaCl, 12 mM M₈Ac₂, 2 mM MnCl₂, 1 mM NaVO₃, 1 μM ATP, and 1 μCi[γ-³²P]ATP, final concentrations) and increasing concentrations of AG-490 (4 μL). After termination by addition of hot sample buffer, the samples are run on a 6% SDS-polyacrylamide gel electrophoresis minigel, the gels dried, and autoradiography performed during the linear exposure time period. The receptor bands are scanned densitrometrically, and the results analyzed by the Ez-Fit program. For the analysis of autophosphorylation of JAK2, JAK2 is immunoprecipitated by using anti-JAK2 antibody from lysates of G2 cells pretreated for 16 hours with increasing concentrations of AG-490 (0-50 μM). Immune complexes are then immunoblotted with anti-phosphotyrosine antibody. A dose-dependent inhibition of in vitro kinase activity is demonstrated by assessing JAK2 autophosphorylation.
Cell Research: ^[2]	- Collapse Cell lines: Pre-B ALL Concentrations: Dissolved in DMSO, final concentrations ~ 50 μM Incubation Time: 16 hours Method: Cells are exposed to different concentrations of AG-490 for 16 hours. For the determination of cell proliferation, [³H]tymidine (1 μCi) is added 6 hours or more before the cultures are terminated. Cells are then collected and samples counted in a liquid scintillation counter. (Only for Reference)
Animal Research: ^[2]	- Collapse Animal Models: SCID mice intravenously injected with ALL cells Dosages: 0.85 mg + 0.5 mg daily Administration: Continuous pump infusion supplemented with daily intraperitoneal injections (Only for Reference)

References

- Collapse

Solubility (25°C)

In vitro	DMSO	58 mg/mL (197.07 mM)
	Water	Insoluble
	Ethanol	'6 mg/mL
In vivo	Add solvents to the product individually and in order(Data is from Selleck tests instead of citations): 5% DMSO+40% PEG300+5% Tween80+50% ddH2O For best results, use promptly after mixing.	6.25 mg/ml

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information Download AG-490 (Tyrphostin B42) SDF

Molecular Weight	294.30
Formula	C₁₇H₁₄N₂O₃
CAS No.	133550-30-8
Storage	3 years-20°C powder 2 years-80°C in solvent
Synonyms	Zinc02557947
Smiles	C1=CC=C(C=C1)CNC(=O)C(=CC2=CC(=C(C=C2)O)O)C#N

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

Dosage

mg/kg

Average weight of animals

Dosing volume per animal

Number of animals

Step 2: Enter the in vivo formulation (Different batches have different solubility ratios, please contact Selleck to provide you with the correct ratio)

% DMSO+ % + % Tween 80+ % ddH₂O

Calculate Reset

Calculation results:

Working concentration： mg/ml；

Method for preparing DMSO master liquid: ： mg drug pre-dissolved in μL DMSO (Master liquid concentration mg/mL， Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation：Take μL DMSO master liquid, next addμL PEG300， mix and clarify, next addμL Tween 80，mix and clarify, next add μL ddH₂O，mix and clarify.

Note：1.Please make sure the liquid is clear before adding the next solvent.
2.Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.

Bio Calculators

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

Serial Dilutions
Concertration (start):
Dilution-folds:

Computed Result

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

Frequently Asked Questions

Question 1:
I would like to know whether AG490 (S1143) goes to CNS through BBB, or not?
Answer:
AG-490 can go through the BBB. You can see this reference: http://bloodjournal.hematologylibrary.org/content/111/4/2062.full.html.

EGFR Signaling Pathway Map

EGFR Inhibitors with Unique Features

Selective EGFR Inhibitor

Erlotinib HCl (OSI-744) : EGFR-selective, IC50=2 nM.
Most Potent EGFR Inhibitor

Afatinib (BIBW2992) : EGFR(wt), IC50=0.5 nM; EGFR(L858R), IC50=0.4 nM; EGFR(L858R/T790M), IC50=10 nM; HER2, IC50=14 nM.
FDA-approved EGFR Inhibitor

Lapatinib : Approved by FDA for breast cancer.
Newest EGFR Inhibitor

CO-1686 (AVL-301) ^New : Irreversible, mutant-selective EGFR inhibitor with K_i of 21.5 nM and 303.3 nM for EGFRL858R/T790M and EGFRWT, respectively.

Related EGFR Products

Erlotinib ^New

Erlotinib (CP358774, NSC 718781) is an EGFR inhibitor with IC50 of 2 nM, >1000-fold more sensitive for EGFR than human c-Src or v-Abl. Erlotinib induces autophagy.
Afatinib (BIBW2992) Dimaleate ^New

Afatinib (BIBW2992) Dimaleate irreversibly inhibits EGFR/HER2 including EGFR(wt), EGFR(L858R), EGFR(L858R/T790M) and HER2 with IC50 of 0.5 nM, 0.4 nM, 10 nM and 14 nM, respectively; 100-fold more active against Gefitinib-resistant L858R-T790M EGFR mutant. Afatinib (BIBW2992) Dimaleate induces autophagy.
Poziotinib (HM781-36B) ^New

Poziotinib (HM781-36B, NOV120101) is an irreversible pan-HER inhibitor with IC50 of 3.2 nM, 5.3 nM and 23.5 nM for HER1, HER2, and HER4, respectively. Poziotinib also induces apoptosis and G1 cell cycle arrest. Phase 2.
Gefitinib (ZD1839)

Gefitinib (ZD-1839, Iressa) is an EGFR inhibitor for Tyr1173, Tyr992, Tyr1173 and Tyr992 in the NR6wtEGFR and NR6W cells with IC50 of 37 nM, 37nM, 26 nM and 57 nM, respectively. Gefitinib promotes autophagy and apoptosis of lung cancer cells via blockade of the PI3K/AKT/mTOR pathway.

Features:A potent EGFR tyrosine kinase inhibitor.
Erlotinib HCl (OSI-744)

Erlotinib HCl (OSI-744, CP358774, NSC 718781) is an EGFR inhibitor with IC50 of 2 nM in cell-free assays, >1000-fold more sensitive for EGFR than human c-Src or v-Abl.
Afatinib (BIBW2992)

Afatinib (BIBW2992) inhibits EGFR/ErbB irreversibly in vitro with IC50 of 0.5, 0.4, 10, 14, 1 nM for EGFR^wt, EGFR^L858R, EGFR^L858R/T790M ErbB2 (HER2) and ErbB4 (HER4), respectively. Afatinib induces autophagy.
Osimertinib (AZD9291)

Osimertinib (AZD9291) is an oral, irreversible, and mutant-selective EGFR inhibitor with IC50 of 12.92, 11.44 and 493.8 nM for Exon 19 deletion EGFR, L858R/T790M EGFR, and WT EGFR in LoVo cells, respectively. Phase 3.
Lapatinib

Lapatinib (GSK572016), used in the form of Lapatinib Ditosylate, is a potent EGFR and ErbB2 inhibitor with IC50 of 10.8 and 9.2 nM in cell-free assays, respectively. Lapatinib induces ferroptosis and autophagic cell death.
Rociletinib (CO-1686)

Rociletinib (CO-1686, AVL-301) is an irreversible, mutant-selective EGFR inhibitor with K_i of 21.5 nM and 303.3 nM for EGFR^L858R/T790M and EGFR^WT in cell-free assays, respectively. Phase 2.
AG-1478 (Tyrphostin AG-1478)

AG-1478 (Tyrphostin AG-1478, NSC 693255) is a selective EGFR inhibitor with IC50 of 3 nM in cell-free assays, almost no activity on HER2-Neu, PDGFR, Trk, Bcr-Abl and InsR. AG-1478 (Tyrphostin AG-1478) inhibits encephalomyocarditis virus (EMCV) and hepatitis c virus (HCV) by targeting phosphatidylinositol 4-kinase IIIα (PI4KA).

Choose Your Country or Region

By Signaling Pathways

By product type

AG-490 (Tyrphostin B42)